Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of IBD98-M in Healthy Volunteers
NCT02196662Phase 1Completed
- Sponsor
- Holy Stone Healthcare Co., Ltd.
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesalamine + sodium hyaluronate in inflammatory bowel disease (IBD) (3 arms), sponsored by Holy Stone Healthcare Co., Ltd. Primary endpoint: Area under the curve in plasma of IBD98-M at Day 5. Started Jul 2014; status: completed.
02
Drugs
mesalamine + sodium hyaluronate
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02196662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196662.